NO20076682L - Nye pyridinanaloger - Google Patents
Nye pyridinanalogerInfo
- Publication number
- NO20076682L NO20076682L NO20076682A NO20076682A NO20076682L NO 20076682 L NO20076682 L NO 20076682L NO 20076682 A NO20076682 A NO 20076682A NO 20076682 A NO20076682 A NO 20076682A NO 20076682 L NO20076682 L NO 20076682L
- Authority
- NO
- Norway
- Prior art keywords
- pyridine analogs
- new pyridine
- formula
- analogs
- new
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000002172 P2Y12 inhibitor Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229960004676 antithrombotic agent Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501663 | 2005-07-13 | ||
| SE0502354 | 2005-10-24 | ||
| PCT/SE2006/000832 WO2007008140A1 (en) | 2005-07-13 | 2006-07-04 | New pyridine analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076682L true NO20076682L (no) | 2008-03-05 |
Family
ID=37637403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076682A NO20076682L (no) | 2005-07-13 | 2007-12-28 | Nye pyridinanaloger |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080312208A1 (https=) |
| EP (1) | EP1904474A4 (https=) |
| JP (1) | JP2009501216A (https=) |
| KR (1) | KR20080039405A (https=) |
| AR (1) | AR054632A1 (https=) |
| AU (1) | AU2006267148A1 (https=) |
| CA (1) | CA2614726A1 (https=) |
| EC (1) | ECSP088140A (https=) |
| IL (1) | IL188293A0 (https=) |
| MX (1) | MX2008000470A (https=) |
| NO (1) | NO20076682L (https=) |
| RU (1) | RU2008101924A (https=) |
| TW (1) | TW200726758A (https=) |
| UY (1) | UY29667A1 (https=) |
| WO (1) | WO2007008140A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080027104A1 (en) * | 2006-07-04 | 2008-01-31 | Astrazeneca Ab | Novel Crystalline Forms 2 |
| US20080009523A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New Pyridine Analogues IV |
| AR064864A1 (es) * | 2007-01-12 | 2009-04-29 | Astrazeneca Ab | Compuestos analogos de piridina vii 543 y composicion farmaceutica |
| US20100137277A1 (en) * | 2007-01-12 | 2010-06-03 | Astrazeneca Ab | Pyridine compounds and their use as p2y12 antagonists |
| UY30868A1 (es) * | 2007-01-12 | 2008-09-02 | Astrazeneca Ab | Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones. |
| US20090018166A1 (en) * | 2007-07-13 | 2009-01-15 | Astrazeneca Ab | New Pyridine Analogues X 161 |
| AR072697A1 (es) * | 2008-07-07 | 2010-09-15 | Astrazeneca Ab | Compuestos de piridina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastorno de agregacion plaquetaria |
| AR074628A1 (es) * | 2008-07-07 | 2011-02-02 | Astrazeneca Ab | Derivados de piridina 2- amino-6-alquil sustituidos utiles como inhibidores de p2y12 308 |
| JP2014051434A (ja) * | 2010-12-28 | 2014-03-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体 |
| WO2013033178A1 (en) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| CN103483274B (zh) * | 2013-09-25 | 2016-03-09 | 江苏快达农化股份有限公司 | 一种制备苄嘧磺隆的方法 |
| US10759781B2 (en) | 2015-08-06 | 2020-09-01 | Ube Industries, Ltd. | Substituted guanidine derivatives |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| DK1257550T3 (da) * | 2000-02-04 | 2006-03-27 | Portola Pharm Inc | Blodplade-ADP-receptor-inhibitor |
| US7452870B2 (en) * | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7018985B1 (en) * | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7132408B2 (en) * | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| FR2820057A1 (fr) * | 2001-01-30 | 2002-08-02 | Ct De Transfert De Technologie | Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane |
| AR037097A1 (es) * | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| DK1466912T3 (da) * | 2002-01-18 | 2013-07-01 | Astellas Pharma Inc | 2-acylaminothiazolderivat eller salt deraf |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| JP4879745B2 (ja) * | 2003-10-03 | 2012-02-22 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 置換イソキノリノン |
| US7504497B2 (en) * | 2003-10-21 | 2009-03-17 | Inspire Pharmaceuticals, Inc. | Orally bioavailable compounds and methods for inhibiting platelet aggregation |
| US7749981B2 (en) * | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| WO2005056354A2 (en) * | 2003-12-03 | 2005-06-23 | Gedeon Anthony A | Method of resisting contaminant build up and oxidation of vehicle surfaces and other surfaces |
| US8071624B2 (en) * | 2004-06-24 | 2011-12-06 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| EP1836189A1 (en) * | 2005-01-06 | 2007-09-26 | AstraZeneca AB | Novel pyridine compounds |
| US20080009523A1 (en) * | 2006-07-04 | 2008-01-10 | Astrazeneca Ab | New Pyridine Analogues IV |
| US20080032992A1 (en) * | 2006-07-04 | 2008-02-07 | Astrazeneca Ab | New Pyridine Analogues V |
| MX2008016562A (es) * | 2006-07-04 | 2009-02-06 | Astrazeneca Ab | Analogos de piridina nuevos. |
-
2006
- 2006-07-04 RU RU2008101924/04A patent/RU2008101924A/ru not_active Application Discontinuation
- 2006-07-04 CA CA002614726A patent/CA2614726A1/en not_active Abandoned
- 2006-07-04 MX MX2008000470A patent/MX2008000470A/es not_active Application Discontinuation
- 2006-07-04 AU AU2006267148A patent/AU2006267148A1/en not_active Abandoned
- 2006-07-04 US US11/995,326 patent/US20080312208A1/en not_active Abandoned
- 2006-07-04 EP EP06758023A patent/EP1904474A4/en not_active Withdrawn
- 2006-07-04 WO PCT/SE2006/000832 patent/WO2007008140A1/en not_active Ceased
- 2006-07-04 KR KR1020087002914A patent/KR20080039405A/ko not_active Withdrawn
- 2006-07-04 JP JP2008521353A patent/JP2009501216A/ja active Pending
- 2006-07-12 UY UY29667A patent/UY29667A1/es not_active Application Discontinuation
- 2006-07-12 AR ARP060102992A patent/AR054632A1/es not_active Application Discontinuation
- 2006-07-13 TW TW095125590A patent/TW200726758A/zh unknown
-
2007
- 2007-12-20 IL IL188293A patent/IL188293A0/en unknown
- 2007-12-28 NO NO20076682A patent/NO20076682L/no not_active Application Discontinuation
-
2008
- 2008-01-25 EC EC2008008140A patent/ECSP088140A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009501216A (ja) | 2009-01-15 |
| CA2614726A1 (en) | 2007-01-18 |
| AR054632A1 (es) | 2007-07-04 |
| EP1904474A4 (en) | 2010-06-16 |
| US20080312208A1 (en) | 2008-12-18 |
| EP1904474A1 (en) | 2008-04-02 |
| IL188293A0 (en) | 2008-04-13 |
| TW200726758A (en) | 2007-07-16 |
| KR20080039405A (ko) | 2008-05-07 |
| MX2008000470A (es) | 2008-03-11 |
| RU2008101924A (ru) | 2009-08-20 |
| WO2007008140A1 (en) | 2007-01-18 |
| AU2006267148A1 (en) | 2007-01-18 |
| UY29667A1 (es) | 2007-02-28 |
| ECSP088140A (es) | 2008-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20085218L (no) | Nye pyridinanaloger | |
| NO20076682L (no) | Nye pyridinanaloger | |
| NO20073101L (no) | Nye pyridinforbindelser | |
| NO20085214L (no) | Nye pyridinanaloger | |
| NO20085213L (no) | Nye pyridinanaloger | |
| NO20085212L (no) | Nye pyridinanaloger | |
| NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
| NO20071504L (no) | Pyrimidinderivanter. | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
| NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
| NO20071776L (no) | Kinoksaliner som B RAF inhibitorer. | |
| NO20071245L (no) | Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer. | |
| NO20072784L (no) | Pyridenkarboksamidderivater for anvendelse som anticancer midler | |
| NO20082709L (no) | Kjemiske forbindelser | |
| NO20074258L (no) | Pyridin-2-karboksamidderivater som MGLUR5 antagonister | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| EP1982982A4 (en) | NEW COUMARINE DERIVATIVE WITH ANTITUM EFFECT | |
| NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
| NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
| NO20070339L (no) | 1-aza-bicyklo[3 3.1]nonaner | |
| NO20090328L (no) | Nye forbindelser 385 | |
| NO20092412L (no) | Hydantoinderivater anvendes som MMP-inhibitorer | |
| NO20063449L (no) | Substituerte heterocykler og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |